Skip to content

CV6 Therapeutics Joins QUBIS “Spin Out to Stand Out” Event at Queen’s University Belfast

13th May 2026

CV6 Therapeutics was proud to participate in “Spin Out to Stand Out,” a recent alumni and innovation event hosted by Queen’s University Belfast and QUBIS on Wednesday, 29 April 2026, highlighting the strength of Northern Ireland’s growing entrepreneurial ecosystem.

As one of QUBIS’ portfolio companies, CV6 joined fellow founders, researchers, investors, and business leaders for conversations focused on innovation, commercialization, and the realities of building companies from academic research and discovery.

CV6 CEO Robert D. Ladner participated in a panel discussion alongside Beckie Ingram of VacTimmune and Dermot Tierney of AMPLY Discovery, sharing perspectives on translating scientific research into real-world impact and the opportunities ahead for Northern Ireland’s life sciences sector.

The evening also featured insights from Frank Graham and Brendan Mooney of Kainos, who reflected on entrepreneurship, innovation, and the long-term growth of Northern Ireland’s technology and business community.

“The strength of Northern Ireland’s innovation ecosystem comes not only from great ideas, but from the collaboration between researchers, founders, investors, mentors, and institutions willing to support long-term growth,” said Ladner. “Events like this reinforce the importance of that community.”

CV6 Therapeutics would like to thank Marina Donohoe, the QUBIS team, and the Queen’s alumni community for organizing such a meaningful event focused on entrepreneurship, innovation, and future growth across the region.

More News

View all
CV6 Announces Initiation of Patient Dosing in CV6-168 Phase 1a Clinical Trial

CV6 Announces Initiation of Patient Dosing in CV6-168 Phase 1a Clinical Trial

CV6 Therapeutics (NI) Ltd. (“CV6”) today announced the successful dosing of the second patient in its Phase 1a study evaluating CV6-168 + infusional 5-fluorouracil (5-FU) in cancer patients.

CV6 Therapeutics Contributes to Discussions on the Future of Oncology Innovation Across Ireland

CV6 Therapeutics Contributes to Discussions on the Future of Oncology Innovation Across Ireland

Dr. Robert D. Ladner, CEO and Founder of CV6 Therapeutics, was invited to join leading voices from industry, healthcare, academia, and government at two major oncology innovation events in Dublin to discuss opportunities to accelerate cancer research, clinical development, and...